Deals
Allergan Seeks Smaller M&A for Growth After Pfizer Breakup
Allergan's Plans for M&A and China
This article is for subscribers only.
Allergan Plc, maker of the anti-wrinkle injection Botox, is hunting for smaller acquisitions to boost growth after its planned $160 billion merger with Pfizer Inc. fell through this year.
"We will be looking at buying intellectual property, R&D assets and of course M&A," Allergan Chief Executive Officer Brent Saunders said in a Bloomberg Television interview in Shanghai on Wednesday. "With respect to M&A, we will be looking at more smaller-scale tuck-in deals that will support our therapeutic area leadership and innovation."